Combined artificial tear medications in the treatment of patients with dry eye syndrome
https://doi.org/10.21516/2072-0076-2022-15-2-154-159
Abstract
In the treatment of patients with dry eye syndrome, the main measure is tear replacement therapy, the most accessible for practicing physicians. It is understandably based on the instillations of artificial tear medications, whose number is steadily growing. In Russia, there are 47 registered medications of this type. Considering the set of requirements for artificial tear medications (which are expected to moisturize the ocular surface, stop the hyperosmolarity of the tear film, ensure osmo-protection and reduce inflammation in the tissues of the ocular surface, as well as activate their reparative regeneration), the most promising medications are those containing two or more active ingredients. One such medication is Oftolik ® medium-viscosity tear substitute that contains a combination of 1.4 % polyvinyl alcohol and 0.6 % polyvinylpyrrolidone. The moisturizing effect of these polymers is complemented by reparative regeneration stimulation (polyvinyl alcohol) and the production of endogenous interferon (polyvinylpyrrolidone). Multiple studies confirmed high clinical efficacy of the medication for the treatment of patients with the main pathogenetic types of dry eye syndrome, as well as its syndromal and secondary symptomatic forms (computer visual syndrome) and revealed. As these effects are achieved with no significant side effects, we can recommend Oftolik® and its preservative-free form Oftolik BK ® for wide clinical use.
Supporting agencies: Author has no financial or property interest in any material or method mentioned
About the Author
V. V. Brzhesky
St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Vladimir V. Brzhesky, Dr. of Med. Sci., professor, head of chair
chair of ophthalmology
194100
2, Litovskaya St.
St. Petersburg
References
1. Stapleton F., Alves M., Bunya V.Y., et al. TFOS DEWS II Epidemiology Report. Ocular Surf. 2017; 15 (3): 334–65. http://dx.doi.org/10.1016/j.jtos.2017.05.003
2. Craig J. P., Nichols K. K., Akpek E. K., et al. TFOS DEWS II Definition and classification report. Ocular Surf. 2017; 15 (3): 276–83. http://dx.doi.org/10.1016/j.jtos.2017.05.008
3. Бржеский В. В. Синдром сухого глаза и заболевания глазной поверхности: клиника, диагностика, лечение / В. В. Бржеский, Г. Б. Егорова, Е. А. Егоров. – Москва: ГЭОТАР-Медиа, 2016. [Brzheskiy V. V., Egorova G. B., Egorov E. A. Dry eye syndrome and ocular surface diseases: clinic, diagnosis, treatment. Moscow: GEOTAR-Media; 2016 (in Russian)].
4. Erickson S., Sullivan A. G., Barabino St., et al. TFOS European Ambassador meeting: Unmet needs and future scientific and clinical solutions for ocular surface diseases. Ocular Surface. 2020; 18 (4): 936–62. https://doi.org/10.1016/j.jtos.2020.05.006
5. Бржеский В. В. Новые возможности слезозамещающей терапии у больных с синдромом сухого глаза различного генеза / В. В. Бржеский [и др.] // Офтальмология. – 2019. – 16 (2): 244–51. [Brzheskiy V. V., Golubev S. Ju., Brzheskaja I. V., Popov V. Ju. New possibilities of tear replacement therapy in patients with dry eye syndrome of various origins Oftal'mologija. 2019; 16 (2): 244–51 (in Russian)]. https://doi.org/10.18008/1816-5095-2019-2-244-251
6. Jones L., Downie L. E., Korb D., et al. TFOS DEWS II Management and therapy report. Ocular Surface. 2017; 15 (3): 575–628. http://dx.doi.org/10.1016/j.jtos.2017.05.006
7. Бржеский В. В. Возможности применения гидроксипропилгуара в слезозаместительной терапии / В. В. Бржеский, С. Ю. Голубев // Вестник офтальмологии. – 2017. – 133 (1): 88–96. [Brzheskiy V. V., Golubev S. Yu. Potential for use of hydroxypropyl guar in tear substitute therapy. Vestnik ophthal'mologii. 2017; 133 (1): 88–96 (in Russian)]. http://dx.doi.org/10.17116/oftalma2017133188-96
8. Krishna N., Brown F. Polyvinyl alcohol as an ophthalmic vehicle: Effect on regeneration of corneal epithelium. Amer. J. Ophthalmol. 1964; 55 (2): 99–106. doi: 10.1016/0002-9394(64)92038-0
9. Алексеева И. В. Разработка лекарственных форм для лечения ран / И. В. Алексеева // Фармация. – 2003. – 2: 43–5. [Alekseyeva I. V. Development of dosage forms for the treatment of wounds. Farmatsiya. 2003; 2: 43–5 (in Russian)].
10. Бржеский В. В. Офтальмохирургия с использованием полимеров / В. В. Бржеский [и др.] ; под ред. В. В. Волкова.– 2-е изд., перераб. и доп. – Санкт-Петербург: Гиппократ; 2009. [Brzheskiy V. V., Volkov V. V., Katayev M. G., et al. Ophthalmic surgery using polymers. In Volkov V. V. eds. Sankt-Petersburg: Gippokrat; 2009 (in Russian)].
11. Brewitt H., Polzer H. Medikamentose Therapie des trockenen Auges. In: Brewitt H., Zierhut M., eds. Trockenes Auge. Heidelberg: Kaden; 2001: 169–82.
12. Jaanus S. D. Lubricants and other preparations for the dry eye. In: Bartlett J. D., Jaanus S. D., eds. Clinical ocular pharmacology. 2nd ed. Boston: Butterworth-Heinemann; 1989: 301–12.
13. Pflugfelder S. C., Stern M. E. Therapy of lacrimal keratoconjunctivitis. In: Pflugfelder S., et al. eds. Dry eye and ocular surface disorders. New York; Basel: Marcel Dekker; 2004: 309–24.
14. Бржеский В. В. Новый препарат искусственной слезы Офтолик ® в лечении больных с синдромом сухого глаза различного генеза / В. В. Бржеский, Л. П. Прозорная // Офтальмологические ведомости. – 2009. – 2 (1): 63–8. [Brzheskiy V. V., Prozornaya L. P. A new drug of artificial tears Oftolik ® in the treatment of patients with dry eye: syndrome of various origins. Oftalmoloicheskye vedomosti. 2009; 2 (1): 63–8 (in Russian)].
15. Майчук Д. Ю. Слезозаместительная терапия при аллергических состояниях глаз / Д. Ю. Майчук [и др.] // Офтальмология. – 2012. –9 (2): 72–6. [Maychuk D. Yu., Chilingaryan L. B., Pronkin I. A., Grigoryan A. R. Tear replacement therapy for allergic eye conditions. Oftalmologiya. 2012; 9 (2): 72–6 (in Russian)].
16. Майчук Ю. Ф. Исследование эффективности применения препарата Офтолик ® в лечении болезни сухого глаза / :- A- Майчук, Е. В. Яни // РМЖ. Клиническая офтальмология. – 2009. – 10 (1): 33–6. [Maychuk Yu. F.. Yani E. V. Study of the efficacy of Oftolik in the treatment of dry eye disease. RMZh. Klinicheskaya oftalmologiya. 2009; 10 (1): 33–6 (in Russian)].
17. Егорова А. В. Применение препаратов Ирифрин (2,5 %) и Офтолик в комплексной терапии компьютерного зрительного синдрома / А. В. Егорова, Е. С. Мыкольникова // Современная оптометрия. – 2012. – 58 (8): 38–42. [Egorova A. V., Mykolnikova E. S. The use of drugs Irifrin (2.5 %) and Oftolik in the complex therapy of computer visual syndrome. Sovremennaya optometriya. 2012; 58 (8): 38–42 (in Russian)].
18. Маркова Е. Ю. Компьютерный зрительный синдром у детей / Е. Ю. Маркова [и др.] // Современная оптометрия. – 2012/ – 58 (9): 43–6. [Markova E. Yu., Kurenkova N. V. Matveyev A. V., et al. Computer vision syndrome in children. Sovremennaya optometriya. 2012; 58 (9): 43–6 (in Russian)].
19. Позднякова В. В. Влияние слезозаместительных глазных капель на сроки эпителизации экспериментальной эрозии роговицы в зависимости от наличия в их составе консерванта / В. В. Позднякова [и др.] // Катарактальная и рефракционная хирургия. – 2012. – 12 (4): 36–9. [Pozdnyakova V. V., Pozdnyakov V. I., Ibragimova D. I., Maychuk Yu. F. Influence of tear-replacing eye drops on the terms of epithelialization of experimental corneal erosion depending on the presence of a preservative in their composition. Kataraktalnaya i refraktsionnaya khirurgiya. 2012; 12 (4): 36–9 (in Russian)].
20. Бржеский В. В. Глаукома и синдром сухого глаза / В. В. Бржеский. – Москва: Компания БОРГЕС, 2018. [Brzheskiy V. V. Glaucoma and dry eye syndrome. Moskva: Kompaniya BORGES; 2018 (in Russian)].
Review
For citations:
Brzhesky V.V. Combined artificial tear medications in the treatment of patients with dry eye syndrome. Russian Ophthalmological Journal. 2022;15(2):154-159. (In Russ.) https://doi.org/10.21516/2072-0076-2022-15-2-154-159
Views:
1118
Email this article 